Strategic partnerships Senseonics actively collaborates with Welldoc to develop the next generation Eversense 365 CGM app, indicating a strong openness to co-development with AI and digital health partners. This suggests sales opportunities in partner-assisted integrations, data platforms, and expanded app ecosystems that can enhance adoption and stickiness.

Eversense 365 focus The company is pushing a one-year CGM system (Eversense 365) and showcasing real-world evidence at major diabetes events. This signals a growing product line and a potential upsell path for clinics and distributors looking to modernize CGM offerings and reduce patient burden.

Clinical outreach Active participation in ADA and scientific sessions indicates a prioritization of clinician-facing education and evidence generation. This creates opportunities to engage endocrinology groups, diabetes centers, and hospital networks with training, case studies, and adoption of long-term CGM solutions.

Mid-market potential Revenue scale and employee range position Senseonics as a smaller, nimble player relative to giants like Dexcom and Medtronic, with potential to win mid-market clinics, specialty centers, and regional healthcare networks seeking implantable CGM options and differentiated value propositions.

Integrated solution sales The combination of implantable CGM technology with AI-powered health solutions via Welldoc points to opportunities for integrated care packages, remote monitoring bundles, and data-driven diabetes management programs that can be sold as standalone offerings or added to existing hospital and payer contracts.